Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2012

View Archived Issues

Novel acetyl-CoA carboxylase 2 inhibitors presented

Taisho reports novel phosphodiesterase 10A inhibitors

Janssen discloses new serotonin 5-HT2B receptor antagonists

Data presented from TRACER and TRAP2P-TIMI 50 vorapaxar trials

Immunotherapy potently reduces LDL cholesterol in phase I trials

Transient receptor potential TRPV1 channel antagonist well tolerated in healthy volunteers

PharmaNeuroBoost clear to commence proof-of-concept PNB-02 trial

Omadacycline noninferior to linezolid in phase III trial

Shionogi and OncoTherapy Science expand licensing agreement

Allergan obtains rights for Ameluz in Spain

ImmunoGen begins phase II IMGN-901 study

Preclinical data support entry of ABTL-0812 into the clinic

ViroMed clear to conduct head-to-head phase III VM-501 study

Roche reports topline data from phase III EMILIA trial

TH-302 gets orphan drug status in E.U. and U.S.

Myriad Genetics and Cephalon enter agreement for mutation testing in phase I/II study

Cardium Therapeutics launches wound care product in U.S.

Portola begins pivotal study of its factor Xa inhibitor

Kyowa Hakko Kirin files application for approval of Parkinson's disease treatment in Japan

Roche divulges novel HDL cholesterol-increasing agents

Novel GCS activators patented by Bayer Schering

First three phase III QVA-149 studies meet primary endpoints

GSK seeks Japanese approval for combination tablet to prevent and treat malaria

Minophagen granted additional rights to bexarotene

Novartis seeks approval for Lucentis line extension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...